The Food and Drug Administration authorized for marketing the first at-home over-the-counter test for COVID-19 using a traditional premarket review pathway rather than emergency use authorities. The Cue COVID-19 Molecular Test detects SARS-CoV-2 in nasal swabs from adults with symptoms of upper respiratory infection. Subsequent devices of the same type with the same intended use that demonstrate substantial equivalence may now use the agency’s 510(k) pathway to obtain clearance, FDA said. 
  
“The FDA continues to proactively work with test developers that desire to market their products beyond emergency use authorities,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “This is part of the FDA’s broader effort to advance the development and availability of at-home tests for a variety of medical conditions to expand patient access to testing.” 

Related News Articles

Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-…